Introduction: The major treatment goal for cerebral palsy children is to provide independence, mainly in those treated with botulinum neurotoxin type A (BoNT-A). Comorbidities, as epilepsy, are common and cause negative impact on treatment results.

Methods: Cross-sectional study evaluated clinical measures, quality of life (PODCI) and biopsychosocial profile (CBCL) among a cohort of patients with hemiplegic cerebral palsy (HCP) treated with BoNT-A. Data were collected from charts and by current evaluations. All patients had encephalic magnetic resonance image (EMRI) and Wechsler Intelligence Scale for Children (WISC-III). Fisher test, Chi-square, Mann-Whitney, ANOVA, Kruskal-Wallis and Spearman coefficient were used and all analyses used a significance level of p<0.05.

Results: Sixty-six patients were included with mean age of 135±55.79 months (57 to 268). Epilepsy was present in 44%. Eleven patients (16.7%) had their EMRI classified as Maldevelopment (MD), 24 (36.4%) Periventricular Atrophy, 22 (36.4%) Cortical/Subcortical Atrophy (CSA), 3 (4.5%) Miscellany and six (9.1%) as Normal. CSA patients had epilepsy more frequently and presented tendency to statistical significance of worse distal upper extremity muscle strength. Patients with epilepsy and MD had lower scores in self-care, sphincters control, communication and total on WeeFIM and in pain and comfort dimension and global function and symptons on PODCI.

Conclusion/Discussion: Epilepsy interferes on treatment results in a cohort of HCP treated with BoNT-A, mainly in patients with EMRI showing MD. This group presents worst functional independence and quality of life.